Allogene Therapeutics Stock Forecast, Price & News

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Allogene Therapeutics stock.
View analyst ratings for Allogene Therapeutics or view top-rated stocks.

Wall Street analysts have given Allogene Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Allogene Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Allogene Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Allogene Therapeutics.

Allogene Therapeutics, Inc. (NASDAQ:ALLO) announced its quarterly earnings results on Tuesday, August, 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.55) by $0.02. The firm had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.95 million.
View Allogene Therapeutics' earnings history.

Allogene Therapeutics' stock was trading at $25.05 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ALLO shares have decreased by 0.7% and is now trading at $24.88.
View which stocks have been most impacted by COVID-19.

10 analysts have issued 1 year target prices for Allogene Therapeutics' stock. Their forecasts range from $40.00 to $55.00. On average, they expect Allogene Therapeutics' share price to reach $44.56 in the next twelve months. This suggests a possible upside of 79.1% from the stock's current price.
View analysts' price targets for Allogene Therapeutics or view top-rated stocks among Wall Street analysts.

2 employees have rated Allogene Therapeutics CEO David Chang on Glassdoor.com. David Chang has an approval rating of 100% among Allogene Therapeutics' employees. This puts David Chang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Allogene Therapeutics include QIAGEN (QGEN), Neurocrine Biosciences (NBIX), CRISPR Therapeutics (CRSP), Acceleron Pharma (XLRN), Vir Biotechnology (VIR), Fate Therapeutics (FATE), Beam Therapeutics (BEAM), Exelixis (EXEL), Denali Therapeutics (DNLI), Halozyme Therapeutics (HALO), Twist Bioscience (TWST), Adaptive Biotechnologies (ADPT), Kodiak Sciences (KOD), Adagio Therapeutics (ADGI) and Abcam (ABCM).
View all of ALLO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), Teladoc Health (TDOC), AbbVie (ABBV), Alibaba Group (BABA), Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP).

(ALLO) raised $272 million in an initial public offering on Thursday, October 11th 2018. The company issued 16,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies served as the underwriters for the IPO.

Allogene Therapeutics trades on the NASDAQ under the ticker symbol "ALLO."

Allogene Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.94%), Vanguard Group Inc. (4.64%), Primecap Management Co. CA (2.52%), Price T Rowe Associates Inc. MD (2.49%), Capital International Investors (2.48%) and Alliancebernstein L.P. (2.24%). Company insiders that own Allogene Therapeutics stock include Alison Moore, Arie Belldegrun, David D Chang, Eric Thomas Schmidt, Group Holdings (Sbs) Advis Tpg, Owen N Witte, Owen N Witte, Rafael Amado and Veer Bhavnagri.
View institutional ownership trends for Allogene Therapeutics.

ALLO stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, Victory Capital Management Inc., PFM Health Sciences LP, Russell Investments Group Ltd., Citadel Advisors LLC, Oppenheimer & Co. Inc., Neuberger Berman Group LLC, and BNP Paribas Arbitrage SA. Company insiders that have sold Allogene Therapeutics company stock in the last year include Alison Moore, Eric Thomas Schmidt, Owen N Witte, Rafael Amado, and Veer Bhavnagri.
View insider buying and selling activity for Allogene Therapeutics or view top insider-selling stocks.

ALLO stock was purchased by a variety of institutional investors in the last quarter, including Primecap Management Co. CA, Morgan Stanley, Morgan Stanley, BlackRock Inc., Renaissance Technologies LLC, State Street Corp, Vanguard Group Inc., and Alliancebernstein L.P..
View insider buying and selling activity for Allogene Therapeutics or or view top insider-buying stocks.

Shares of ALLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALLO stock can currently be purchased for approximately $24.88.

Allogene Therapeutics has a market capitalization of $3.54 billion. The company earns $-250,220,000.00 in net income (profit) each year or ($2.08) on an earnings per share basis.

Allogene Therapeutics employs 265 workers across the globe.

The official website for Allogene Therapeutics is www.allogene.com.

Allogene Therapeutics is headquartered at 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080.

Allogene Therapeutics' mailing address is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (650) 457-2700 or via email at [email protected].